Literature DB >> 30108863

Synergic modulation of the inflammatory state of macrophages utilizing anti-oxidant and phosphatidylserine-containing polymer-lipid hybrid nanoparticles.

Md Zahangir Hosain1, Kazuki Yuzuriha1, Masafumi Takeo1, Akihiro Kishimura1,2,3,4, Yoshihiko Murakami5, Takeshi Mori1,2,3, Yoshiki Katayama1,2,3,4,6,7.   

Abstract

Inflammatory activation of macrophages is a key factor in chronic inflammatory diseases such as ulcerative colitis. The excessive production of reactive oxygen species (ROS)/reactive nitrogen species (RNS) by macrophages causes oxidative stress during the inflammatory response and exaggerates inflammatory lesions in ulcerative colitis. Inhibition of the inflammatory activation of macrophages is a promising treatment for chronic inflammatory diseases. Here, we prepared self-filling polymer-lipid hybrid nanoparticles (PST-PLNPs) consisting of poly dl-lactic acid as a hydrophobic biodegradable polymer core encapsulating α-tocopherol (T) and phosphatidylserine (PS) both on the surface and interior of the particle. We confirmed the anti-inflammatory response of these hybrid nanoparticles in activated murine macrophages. PS has anti-inflammatory effects on macrophages by modulating the macrophage phenotype, while α-tocopherol is an antioxidant that neutralizes ROS. We found that PS-containing (PS-PLNPs) and PS plus α-tocopherol-containing (PST-PLNPs) polymer-lipid hybrid nanoparticles significantly increased the viability of lipopolysaccharide (LPS)-treated macrophages compared with phosphatidylcholine-containing PLNPs. PST-PLNPs had a better effect than PS-PLNPs, which was attributed to the synergy between PS and α-tocopherol. This synergic action of PST-PLNPs reduced NO and pro-inflammatory cytokine (IL-6) production and increased anti-inflammatory cytokine (TGF-β1) production when incubated with activated macrophages. Thus, these self-filling biodegradable polymer-lipid hybrid nanoparticles (PST-PLNPs) containing anti-oxidant and anti-inflammatory molecules might be potential alternative drug carriers to liposomes and polymeric nanoparticles for the treatment of chronic inflammatory diseases such as ulcerative colitis.

Entities:  

Year:  2017        PMID: 30108863      PMCID: PMC6071953          DOI: 10.1039/c7md00174f

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  47 in total

Review 1.  Scavenger receptors in homeostasis and immunity.

Authors:  Johnathan Canton; Dante Neculai; Sergio Grinstein
Journal:  Nat Rev Immunol       Date:  2013-08-09       Impact factor: 53.106

2.  The European consensus on ulcerative colitis: new horizons?

Authors:  Eduard F Stange; Simon P L Travis
Journal:  Gut       Date:  2008-04-30       Impact factor: 23.059

3.  Relaxation of distal colonic circular smooth muscle by nitric oxide derived from human leucocytes.

Authors:  S J Middleton; M Shorthouse; J O Hunter
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

4.  Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.

Authors:  W Kruis; S Schreiber; D Theuer; J W Brandes; E Schütz; S Howaldt; B Krakamp; J Hämling; H Mönnikes; I Koop; M Stolte; D Pallant; U Ewald
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

5.  Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis.

Authors:  R William Vandivier; Valerie A Fadok; Peter R Hoffmann; Donna L Bratton; Churee Penvari; Kevin K Brown; Joseph D Brain; Frank J Accurso; Peter M Henson
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

6.  Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase.

Authors:  M Goppelt-Struebe; D Wolter; K Resch
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

7.  Potential role of nitric oxide in a model of chronic colitis in rhesus macaques.

Authors:  K A Ribbons; X J Zhang; J H Thompson; S S Greenberg; W M Moore; C M Kornmeier; M G Currie; N Lerche; J Blanchard; D A Clark
Journal:  Gastroenterology       Date:  1995-03       Impact factor: 22.682

8.  The free radical scavenger edaravone suppresses experimental dextran sulfate sodium-induced colitis in rats.

Authors:  Yoshio Araki; Akira Andoh; Yoshihide Fujiyama
Journal:  Int J Mol Med       Date:  2003-07       Impact factor: 4.101

9.  IFN-gamma enhances production of nitric oxide from macrophages via a mechanism that depends on nucleotide oligomerization domain-2.

Authors:  Sabine Tötemeyer; Mark Sheppard; Adrian Lloyd; David Roper; Christopher Dowson; David Underhill; Peter Murray; Duncan Maskell; Clare Bryant
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

10.  Corticosteroid-related central nervous system side effects.

Authors:  Miriam Ciriaco; Pasquale Ventrice; Gaetano Russo; Maria Scicchitano; Giovanni Mazzitello; Francesca Scicchitano; Emilio Russo
Journal:  J Pharmacol Pharmacother       Date:  2013-12
View more
  1 in total

Review 1.  Cell-Inspired Biomaterials for Modulating Inflammation.

Authors:  Elizabeth C Bender; Chelsea A Kraynak; Wenbai Huang; Laura J Suggs
Journal:  Tissue Eng Part B Rev       Date:  2021-07-29       Impact factor: 7.376

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.